A large number of drugs may interfere with the hair cycle and produce hair loss. Drugs may affect anagen follicles through 2 main different modalities: (i) by inducing an abrupt cessation of mitotic activity in rapidly dividing hair matrix cells (anagen effluvium) or (ii) by precipitating the follicles into premature rest (telogen effluvium). In anagen effluvium, hair loss usually occurs within days to weeks of drug administration, whereas in telogen effluvium, hair loss becomes evident 2 to 4 months after starting treatment.
Anagen effluvium is a prominent adverse effect of antineoplastic agents, which cause acute damage of rapidly dividing hair matrix cells. Telogen effluvium may be a consequence of a large number of drugs including anticoagulants, retinol (vitamin A) and its derivatives, interferons and antihyperlipidaemic drugs. Drug-induced hair loss is usually reversible after interruption of treatment. The prevalence and severity of alopecia depend on the drug as well as on individual predisposition. Some drugs produce hair loss in most patients receiving appropriate dosages while other drugs are only occasionally responsible for hair abnormalities.
Both hirsutism and hypertrichosis may be associated with drug administration. Drugs most commonly responsible for the development of hirsutism include testosterone, danazol, corticotrophin (ACTH), metyrapone, anabolic steroids and glucocorticoids. Hypertrichosis is a common adverse effect of cyclosporin, minoxidil and diazoxide.
Hair Loss Tretinoin Hair Growth Diazoxide Minoxidil
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Baldelli A, Rebora A. Telogen effluvium and minoxidil. Journal of the American Academy of Dermatology 21: 572–573, 1989CrossRefGoogle Scholar
Bencini PL, Montagnino G, Sala F, et al. Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients. Dermatologica 172: 24–30, 1986PubMedCrossRefGoogle Scholar
Buhl AE, Waldon SJ, Conrad MJ, et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. Journal of Investigative Dermatology 98: 315–319, 1992PubMedCrossRefGoogle Scholar
Burton JL, Schutt WH, Caldwell IW. Hypertrichosis due to diazoxide. British Journal of Dermatology 93: 707–711, 1975PubMedCrossRefGoogle Scholar
Caputo R, Monti M, Motta S, et al. The treatment of visible signs of senescence: the Italian experience. British Journal of Dermatology 112 (Suppl. 35): 97–103, 1990CrossRefGoogle Scholar
Cohen DJ, Loertscher R, Rubin MF, et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Annals of Internal Medicine 10: 667–682, 1984Google Scholar
Fenton DA, English JS, Wilkinson JD. Reversal of male-pattern baldness, hypertrichosis, and accelerated hair and nail growth in patients receiving benoxaprofen. British Medical Journal 284; 1228–1229, 1982PubMedCrossRefGoogle Scholar
Finzi AF. Cyclosporin in severe psoriasis: the Italian experience. Dermatology 187 (Suppl. 1): 1–44, 1993CrossRefGoogle Scholar